If WE are the ones buying Shire then why...

Discussion in 'Takeda' started by anonymous, Jan 8, 2019 at 2:56 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Is Shire the one's calling all the shots and making all the decisions on how the "purchase" will be done and who will be let go in the downsizing and where the headquarters will be located? Futhermore, why do all the headcount decisions have to be "blessed" by the Shire board before they are put into the final plan that will be rolled out to everyone at the end of this month?

    Sure seems more like Shire is buying us. Brace for some seriously bad news if you are from the Takeda side of this shit show.
     
  2. anonymous

    anonymous Guest

    Because this is was Takeda agreed to.
     
  3. anonymous

    anonymous Guest

    What are you talking about with the final plan being rolled out at the end of the month? Where did you get this information. Shire employee here and we haven’t heard that or that timeline.
     
  4. anonymous

    anonymous Guest

    It's just some idiot with 5% of the information trying to stir up s**t. I wouldn't read into it one way or the other.
     
  5. anonymous

    anonymous Guest

    Really? I think the OP is dead on. I've heard they are ironing out structure, head count and major change in reporting (more integrated structure with less redundency) and all change finalization has to be signed off on by Shire ELT. They are running the show and not Takeda ELT. I'm hearing Shire making all the decisions and Takeda ELT just laying down and rolling over for the Shire peeps. Lower level Takeda employees who are part of the change team are getting very frustrated that it is starting to feel like Shire has been given all or most of the decision making.

    Could anyone please elaborate please?
     
  6. anonymous

    anonymous Guest

    Elaborate on what? Sounds like you are “hearing” a lot.
     
  7. anonymous

    anonymous Guest

    I think she wants someone to elaborate on the specifics. I've also heard that Shire is in charge and making all the decisions. I want to know how much of a reduction in headcount? Are most to be severed from Takeda? Who will be head of each division? What will severance look like?...

    I think that is what the poster was hoping someone could elaborate on. We know decisions have been made.
     
  8. anonymous

    anonymous Guest

    Sounds like you had a few glasses of wine before typing this post. Keep dreaming...Shire ain’t in charge of anything.
     
  9. anonymous

    anonymous Guest

    Takeda will bow and kiss the ring of the Shire Golden Goose
     
  10. anonymous

    anonymous Guest

    So true. Takeda best be tellin their people that are working with the Shire people on the "transition/downsizing" plan to keep their lips from flappin. It's common knowledge from those involved that Shire is firmly making all the decisions and that their executives are smarter and much more disciplined than the Takeda people. That's what I'm hearing.
     
  11. anonymous

    anonymous Guest

    That's ridiculous. Sounds more like wishful thinking to me.
     
  12. anonymous

    anonymous Guest

    Yeah? You know what I’m hearing? Wishful thinking from a very nervous Shire employee...
     
  13. anonymous

    anonymous Guest

    You are all just a bunch of speculating reps that literally have no idea

    Read what’s been posted and there is proof that all this is speculation from a moron.

    1. Look at timeline posted. Obviously something happening between between end of February and early May.
    2. Just listed top 200 execs. Doesn’t really look to shire heavy does it.
    3. Look at the heads of different business units. Nuero and GI is Takeda heavy, the rest Shire heavy.
    4. Vivance expiration date is closer than trintellix. Both drugs easy to learn. What makes more sense here?
    5. A Takeda leader has already stated importance of of calling on primary care. Who is already doing this?
    6. Look at $ that need to be saved. $1.4 billion over 3 years. 53% coming from all combined overlap from sales marketing and IT. That’s roughly 234 million/ year. That’s falls somewhere between 800-1000 employees combined from both companies. Take away home office marketing and IT jobs from that
    Will leave some 500 sales jobs. 50-60 being DM or RD level.
    Between 2 sales forces it’s going to be around 450 reps.
    Unfortunately there will be some good reps let go due to overlap But mostly underperforming.
    Go look at the last Cresset report and you can probably pick out the easy ones that will be gone. Shire will have their bafoons let go as well. So, if you are rep reading this, and you have overlap in your territory and you are in the bottom 15% in cresset fair warning you should start looking now or wait out a severance.
    If it all works out we cut out non performing lazy old school thinking reps and DMs and left with a motivated hard working thinking group of real people.
     
  14. anonymous

    anonymous Guest

    You’re a unethical non performing lazy old school company that screws up everything, do everyone a favor and pack it back to Japan

    Quote
     
  15. anonymous

    anonymous Guest

    Good evening gang,
    We appreciate all your efforts out there and just know in this time of uncertainty; we will keep you informed as soon as we are able to.

    In the meantime, business as usual and gang, roll up and questions you may have but we appreciate all you do for the patients you serve ..

    A certain new BU leader...
     
  16. anonymous

    anonymous Guest

    Good evening gang.

    Perry and Mark R said we are getting let go in mass numbers.

    Buckle up kiddies and meet me on political board for some man on man:cool:
     
  17. anonymous

    anonymous Guest

    ‘Simple’.... Takeda bought Shire. So Takeda is the boss. Takeda will use this opportunity to get rid of any deadwood from Takeda by replacing with Shire folks. So far...replacement with Shire folks has been minimal
     
  18. anonymous

    anonymous Guest

    It has nothing to do with lazy reps, that’s just BS. If there’s overlap you are gone and Shire neuro will feel the brunt of this but Takeda employees will be hurt as well. Vyvanse is protected until 2023, Mydayis is a dog, that being said too much money was spent and there will be a massive consolidation in these BU’s. Another point is in rare disease Shire names are prevalent because they have experience in these areas, that’s all. The number of reps is minimal in all the rare disease spaces the obu and NBU make up almost 600-700 reps and most of us know we are in trouble.
    Speaking from the shire side we haven’t heard much except business as usual. It’s a terrible situation that people will lose their jobs for an overvalued purchase. Shire was in big trouble for years due to poor acquisitions, competition from better competitors in hemophilia, expiration date in Neuro with no pipeline, and an underperforming dry eye division to name a few. Good luck to everyone it’s going to be ugly.
     
  19. anonymous

    anonymous Guest

     
  20. anonymous

    anonymous Guest

    The question is WHEN? They won't tell us anything!